PLS shares trade at half their five-year sales multiple

A compressed multiple has a mechanical consequence. At a fixed ratio, the share price moves in line with revenue; revenue growth at a static multiple simply lifts the price at the same clip, and a falling revenue line does the arithmetic in reverse. The ratio forecasts neither path. It only sets the relationship between the two.

Over a full five years, the average multiple ran at nearly double today’s reading. That window spans very different lithium price conditions, and the gap is a measure of how much the market now pays for each dollar of Pilbara’s sales relative to the past five years. A gap that size, on a stock whose revenue kept growing, is what pushes the Rask Media analysis toward caution. The piece presents both possibilities and says revenue has, in fact, been growing. Then comes the caveat: a single multiple is a rough starting point, not a verdict.

A second valuation in the same analysis makes the point. Pro Medicus (ASX: PME), the radiology software provider founded in 1983, trades at 104.93x sales against a five-year average of 82.69x, above its own history. Pilbara sits below its own. The two businesses explain the two ratios. Pro Medicus’s flagship Visage software lets radiologists read scans on mobile devices, and the company earns recurring revenue from hospitals and imaging centres; Pilbara sells a commodity whose price is set by each new cargo. Same metric, opposite positions.

Price-to-sales also skips the cost side of the equation. Two miners can carry the same sales multiple with very different margins and debt loads, and nothing in the ratio captures what it costs to produce those sales. For a commodity producer, the revenue line itself is set by volumes and the commodity price; the denominator can move on its own, independent of the share price.

The Rask Media analysis closes with its own caveat: the multiple is “a rough starting point,” and investment decisions “can’t just be based on one metric.” For Pilbara, the starting point is a ratio at roughly half its five-year average; the revenue line behind it has grown for three straight years. The spodumene price, which the analysis says moves in sometimes dramatic swings, sets the size of that revenue line. The multiple records what the price has already done to the revenue line, and nothing more.